References
1. Crisp HC, Johnson KS. Mosquito allergy. Ann Allergy, Asthma
Immunol . 2013;110(2):65-69. doi:10.1016/j.anai.2012.07.023
2. Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease.Front Immunol . 2017;8(DEC):1-6. doi:10.3389/fimmu.2017.01867
3. Cantillo JF, Fernández-Caldas E, Puerta L. Immunological aspects of
the immune response induced by mosquito allergens. Int Arch
Allergy Immunol . 2014;165(4):271-282. doi:10.1159/000371349
4. Quanti e quali tipi di zanzare esistono in Italia? Accessed June 4,
2021.
https://www.greenme.it/vivere/salute-e-benessere/tipi-zanzare-esistenti-italia/
5. Cantillo JF, Puerta L, Lafosse-Marin S, Subiza JL, Caraballo L,
Fernández-Caldas E. Identification and Characterization of IgE-Binding
Tropomyosins in Aedes aegypti. Int Arch Allergy Immunol .
2016;170(1):46-56. doi:10.1159/000447298
6. Sabbah A, Hassoun S, Drouet M, Lauret MG, Doucet M. [The
wasp/mosquito syndrome]. Allerg Immunol (Paris) .
1999;31(6):175-184. http://www.ncbi.nlm.nih.gov/pubmed/10443298
7. Scala E, Pirrotta L, Uasuf CG, et al. Aedes communis Reactivity Is
Associated with Bee Venom Hypersensitivity: An in vitro and in vivo
Study. Int Arch Allergy Immunol . 2018;176(2):101-105.
doi:10.1159/000488866
8. Peng Z, Beckett AN, Engler RJ, Hoffman DR, Ott NL, Simons FER. Immune
responses to mosquito saliva in 14 individuals with acute systemic
allergic reactions to mosquito bites. J Allergy Clin Immunol .
2004;114(5):1189-1194. doi:10.1016/j.jaci.2004.08.014
9. Palosuo K, Brummer-Korvenkontio H, Mikkola J, Sahi T, Reunala T.
Seasonal increase in human ige and lgg4 antisaliva antibodies to aedes
mosquito bites. Int Arch Allergy Immunol . 1997;114(4):367-372.
doi:10.1159/000237696
10. Ariano R, Panzani RC. Efficacy and safety of specific immunotherapy
to mosquito bites. Eur Ann Allergy Clin Immunol .
2004;36(4):131-138. http://www.ncbi.nlm.nih.gov/pubmed/15180354
11. Srivastava D, Singh BP, Sudha VT, Arora N, Gaur SN. Immunotherapy
with mosquito (Culex quinquefasciatus) extract: a double-blind,
placebo-controlled study. Ann Allergy Asthma Immunol .
2007;99(3):273-280. doi:10.1016/S1081-1206(10)60664-3
12. Manrique MA, González-Díaz S, Arias-Cruz A, et al. Efficacy of
Immunotherapy With Allergenic Extract of Aedes Aegypti in the Treatment
of Large Local Reaction to Mosquito Bites in Children. World
Allergy Organ J . 2012;5:S147. doi:10.1097/01.WOX.0000411578.60734.e0
13. Benaim-Pinto C, Fassrainer A. Intradermal immunotherapy in children
with severe skin inflammatory reactions to Aedes aegypti and Culex
quinquefasciatus mosquito bites. Int J Dermatol .
1990;29(8):600-601. doi:10.1111/j.1365-4362.1990.tb03479.x
14. McCormack DR, Salata KF, Hershey JN, Carpenter GB, Engler RJ.
Mosquito bite anaphylaxis: Immunotherapy with whole body extracts.Ann Allergy . 1995;74(1):39-44.
15. Manning JE, Oliveira F, Coutinho-Abreu I V., et al. Safety and
immunogenicity of a mosquito saliva peptide-based vaccine: a randomised,
placebo-controlled, double-blind, phase 1 trial. Lancet .
2020;395(10242):1998-2007. doi:10.1016/S0140-6736(20)31048-5
16. Reiter N, Reiter M, Altrichter S, et al. Case Report Anaphylaxis
caused by mosquito allergy in systemic mastocytosis. Lancet .
2013;382(9901):1380. doi:10.1016/S0140-6736(13)61605-0
17. Galindo PA, Gómez E, Borja J, et al. Mosquito bite hypersensitivity.Allergol Immunopathol (Madr) . 26(5):251-254.
http://www.ncbi.nlm.nih.gov/pubmed/9885733
18. García Ortiz JC, Cosmes Martín P. [Anaphylaxis from a mosquito
bite]. Med Clin (Barc) . 1994;102(4):157.
http://www.ncbi.nlm.nih.gov/pubmed/7907159
19. Hassoun S, Drouet M, Sabbah A. [Anaphylaxis caused by a mosquito:
2 case reports]. Allerg Immunol (Paris) . 1999;31(8):285-287.
http://www.ncbi.nlm.nih.gov/pubmed/10572584
20. Mueller HL. Further Experiences with Severe Allergic Reactions to
Insect Stings. N Engl J Med . 1959;261(8):374-377.
doi:10.1056/nejm195908202610803
21. Bonadonna P, Lombardo C, Zanotti R. Mastocytosis and Allergic
Diseases . Vol 24.; 2014. Accessed November 1, 2018.
http://www.jiaci.org/issues/vol24issue5/1.pdf
22. Karppinen A, Brummer-Korvenkontio H, Petman L, Kautiainen H, Hervé
JP, Reunala T. Levocetirizine for treatment of immediate and delayed
mosquito bite reactions. Acta Derm Venereol . 2006;86(4):329-331.
doi:10.2340/00015555-0085
23. Karppinen A, Brummer-Korvenkontio H, Reunala T, Izquierdo I.
Rupatadine 10 mg in the treatment of immediate mosquito-bite allergy.J Eur Acad Dermatology Venereol . 2012;26(7):919-922.
doi:10.1111/j.1468-3083.2012.04543.x
24. Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen
immunotherapy: Hymenoptera venom allergy. Allergy Eur J Allergy
Clin Immunol . 2018;73(4):744-764. doi:10.1111/all.13262
25. Knibb RC, Huissoon AP, Baretto R, et al. “It’s not an illness, it’s
just bad luck”: The impact of anaphylaxis on quality of life in adults.Clin Exp Allergy . 2019;49(7):1040-1046. doi:10.1111/cea.13410
26. Licari A, Marseglia G, Castagnoli R, Marseglia A, Ciprandi G. The
discovery and development of omalizumab for the treatment of asthma.Expert Opin Drug Discov . 2015;10(9):1033-1042.
doi:10.1517/17460441.2015.1048220
27. Maurer M, Rosén K, Hsieh H-J, et al. Omalizumab for the Treatment of
Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med .
2013;368(10):924-935. doi:10.1056/NEJMoa1215372
28. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that
contribute to efficacy of omalizumab in chronic spontaneous urticaria.Allergy . 2017;72(4):519-533. doi:10.1111/all.13083
29. Lam V, Kalesnikoff J, Lee CWK, et al. IgE alone stimulates mast cell
adhesion to fibronectin via pathways similar to those used by IgE +
antigen but distinct from those used by Steel factor. Blood .
2003;102(4):1405-1413. doi:10.1182/blood-2002-10-3176
30. Kalesnikoff J, Huber M, Lam V, et al. Monomeric IgE stimulates
signaling pathways in mast cells that lead to cytokine production and
cell survival. Immunity . 2001;14(6):801-811.
doi:10.1016/S1074-7613(01)00159-5
31. Da Silva EN, Randall KL. Omalizumab mitigates anaphylaxis during
ultrarush honey bee venom immunotherapy in monoclonal mast cell
activation syndrome. J Allergy Clin Immunol Pract .
2013;1(6):687-688. doi:10.1016/j.jaip.2013.07.004
32. Carter MC, Maric I, Brittain EH, et al. A randomized double-blind,
placebo-controlled study of omalizumab for idiopathic anaphylaxis.J Allergy Clin Immunol . 2021;147(3):1004-1010.e2.
doi:10.1016/j.jaci.2020.11.005
33. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA.
Kinetics of mast cell, basophil, and oral food challenge responses in
omalizumab-treated adults with peanut allergy. J Allergy Clin
Immunol . 2012;130(5). doi:10.1016/j.jaci.2012.05.039
34. MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates
rapid oral desensitization for peanut allergy. J Allergy Clin
Immunol . 2017;139(3):873-881.e8. doi:10.1016/j.jaci.2016.08.010
35. Pałgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination
of omalizumab and specific immunotherapy for severe anaphylaxis after a
wasp sting. Int J Immunopathol Pharmacol . 2014;27(1):109-112.
doi:10.1177/039463201402700114
36. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe
anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and
concurrent treatment with omalizumab. J Investig Allergol Clin
Immunol . 2009;19(3):225-229.
http://www.ncbi.nlm.nih.gov/pubmed/19610266
37. Ricciardi L. Omalizumab: A useful tool for inducing tolerance to bee
venom immunotherapy. Int J Immunopathol Pharmacol .
2016;29(4):726-728. doi:10.1177/0394632016670920
38. Gülsen A, Ruëff F, Jappe U. Omalizumab ensures compatibility to bee
venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient
with systemic mastocytosis. Allergol Sel . 2021;5(01):128-132.
doi:10.5414/alx02196e
39. Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab
monotherapy for bee sting and unprovoked “anaphylaxis” in a patient
with systemic mastocytosis and undetectable specific IgE. Ann
Allergy, Asthma Immunol . 2010;104(6):537-539.
doi:10.1016/j.anai.2010.04.011
40. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe
DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients
with systemic mastocytosis. J Allergy Clin Immunol .
2007;119(6):1550-1551. doi:10.1016/j.jaci.2007.03.032
41. Broesby-Olsen S, Vestergaard H, Mortz CG, et al. Omalizumab prevents
anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and
safety observations. Allergy Eur J Allergy Clin Immunol .
2018;73(1):230-238. doi:10.1111/all.13237
42. Lemal R, Fouquet G, Terriou L, et al. Omalizumab Therapy for Mast
Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. J
Allergy Clin Immunol Pract . 2019;7(7):2387-2395.e3.
doi:10.1016/j.jaip.2019.03.039
43. Sanchez-Valenzuela MC, Garcia-Saucedo JC, Motoa G, Carrillo-Martin
I, Gonzalez-Estrada A. Treatment of idiopathic anaphylaxis with
omalizumab. Ann Allergy, Asthma Immunol . 2019;123(6):612-613.
doi:10.1016/j.anai.2019.09.020
44. Bilò MB, Martini M, Tontini C, Mohamed OE, Krishna MT. Idiopathic
anaphylaxis. Clin Exp Allergy . 2019;49(7):942-952.
doi:10.1111/cea.13402